STELLA PHARMA will launch Steboronine®, the World’s First BNCT Drug, on May 20, 2020

STELLA PHARMA CORPORATION (Head office: Chuoku, Osaka City; President: Tomoyuki Asano) is pleased to announce that Steboronine® intravenous drip bag 9000 mg/300 mL (Generic name: Borofalan [10B]; “Steboronine®”), a boron drug for boron neutron capture therapy (“BNCT”), has been listed on the National Health Insurance Drug Price List, as published in the Official Gazette today (May 19,2020). We are also pleased to announce that the product will be available for sale on May 20.

STELLA PHARMA will launch Steboronine® , the World’s First BNCT Drug, on May 20, 2020 ダウンロード

The phase II study of recurrent or locally advanced head and neck cancer in Japan has published in “Radiotherapy and Oncology” The phase II study of recurrent glioblastoma in Japan has published in “Neuro-Oncology Advances”